{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-127507","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.447022+00:00","generated_at":"2026-06-07T09:57:18.513939+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Passage Bio reports promising Phase 1/2 data for PBFT02 in FTD-GRN; shifts strategy to adult neurodegenerative diseases","bullets":["Dose 1 of PBFT02 achieved 3.6-6.6-fold increase in CSF PGRN at day 30, reaching supraphysiologic levels of 10.7-17.3 ng/mL.","PBFT02 was generally well-tolerated with enhanced steroid regimen; no serious AEs in patients 2 and 3.","Company to focus on PBFT02 in FTD-GRN, FTD-C9orf72, ALS, and Alzheimer's; seeking partnerships for pediatric programs.","Expects to initiate dosing of Cohort 2 in 1H 2024 and report full 6-month data from Cohort 1 in 2H 2024.","Estimates FTD-GRN prevalence at ~18,000 patients in US and Europe; exploring PBFT02 in larger indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-127507","json":"https://secwatch.observer/filing/0001104659-23-127507.json","markdown":"https://secwatch.observer/filing/0001104659-23-127507.md","text":"https://secwatch.observer/filing/0001104659-23-127507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923127507/0001104659-23-127507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923127507/tm2332555d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:57:18.513939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}